GRI GRI Bio, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
14:06
Jan 10
Jan 10
Micro-cap GRI Bio IPF data, buyout catalyst
The author argues GRI Bio is a high-risk micro-cap with a large gap between its ~$0.28 price and analyst targets of $10-$30. The claimed mechanism is positive Phase 2a data (Jan 2026) for lead drug GRI-0621 in IPF, which reportedly stopped lung function decline in twice as many patients versus standard care. An $8 million December offering is said to resolve Nasdaq minimum-equity compliance, and the next Phase 2b could be a catalyst for a big pharma buyout or partnership. The author explicitly flags this as a high-risk micro-cap play.
HIGH
About GRI Investor Commentary
Across the available history and selected sources, Buzzberg tracks GRI (GRI Bio, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Richoffpurp.